ANI Pharmaceuticals Q2 2024 Adj. EPS $1.02 Beats $0.95 Estimate, Sales $138.040M Beat $129.054M Estimate
Portfolio Pulse from Benzinga Newsdesk
ANI Pharmaceuticals reported Q2 2024 adjusted EPS of $1.02, beating the estimate of $0.95. Sales for the quarter were $138.040 million, surpassing the expected $129.054 million.
August 06, 2024 | 10:51 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
ANI Pharmaceuticals reported better-than-expected Q2 2024 earnings and sales, with adjusted EPS of $1.02 beating the $0.95 estimate and sales of $138.040 million surpassing the $129.054 million forecast.
The better-than-expected earnings and sales figures are likely to positively impact ANIP's stock price in the short term as they indicate strong financial performance.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100